Skip to content

Clinical Features and Prognostic Markers in Adult Patients With AE Requiring ICU Treatment

Clinical Features and Prognostic Markers in Adult Patients With AE Requiring ICU Treatment

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06456736
Enrollment
200
Registered
2024-06-13
Start date
2024-06-30
Completion date
2024-08-31
Last updated
2024-06-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autoimmune Encephalitis

Brief summary

Autoimmune encephalitis (AE) is a potentially life-threatening inflammation of the central nervous system (CNS) and constitutes 20%-30% of encephalitis cases in adults AE often leads to subacute, severe, and debilitating encephalitis necessitating long-term management in a neurologic intensive care unit (ICU). This study aims to explore the predictive factors for poor clinical outcomes by analyzing the clinical characteristics and prognosis of adult patients with critical AE requiring ICU admission. Prospective observational single center study in neurologic ICU, the second Xiangya hospital, Central South University. All patients admitted to the ICU for probable or confirmed AE (2022 Chinese guidelines for diagnosis and treatment of AE) will be included. Factors associated with a poor prognosis will be identified by multivariate analysis using a logistic regression.

Interventions

Not applicable, non-interventional study

Sponsors

Central South University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
15 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Diagnosed as either ''definite'' or ''probable'' AE based on Chinese guidelines for diagnosis and treatment of AE (version 2022) * Age ≥ 15 years * Admission to an adult ICU during the course of the disease

Exclusion criteria

* Missing data on primary outcome * ICU length of stay of 24 hours or less.

Design outcomes

Primary

MeasureTime frameDescription
Modified Rankin Scale12 monthsThe modified Rankin Scale (mRS) is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. It has become the most widely used clinic. mRS is scored on a scale of 0 to 6. The higher the score, the worse the prognosis

Secondary

MeasureTime frameDescription
Mortality12 monthsRate of death at 12 months
Rate of complications12 monthsSeptic shock, hyponatremia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026